Corbus Pharmaceuticals Holdings (CRBP) Non-Current Debt (2013 - 2024)

Corbus Pharmaceuticals Holdings has reported Non-Current Debt for 6 years, with the latest figure at $10.7 million in Q2 2024.

• On a quarterly basis, Non-Current Debt fell 5.08% year-over-year to $10.7 million in Q2 2024; TTM through Jun 2024 was $10.7 million, a 5.08% decrease from a year earlier, with the FY2023 full-year figure at $15.9 million, changed 0.48% from the prior year.
• Non-Current Debt was $10.7 million for Q2 2024 at Corbus Pharmaceuticals Holdings, down from $15.9 million in the prior quarter.
• The five-year high for Non-Current Debt was $18.6 million in Q3 2021, with the low at $9.4 million in Q3 2022.
• Average Non-Current Debt over 5 years is $14.9 million, with a median of $15.8 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: Non-Current Debt climbed 3.89% in 2021, then slumped 49.4% in 2022.
• Over 5 years, Non-Current Debt stood at $18.0 million in 2020, then declined by 13.27% to $15.6 million in 2021, then advanced by 2.23% to $16.0 million in 2022, then fell by 0.48% to $15.9 million in 2023, then plunged by 32.46% to $10.7 million in 2024.
• The last three Non-Current Debt figures came in at $10.7 million (Q2 2024), $15.9 million (Q4 2023), and $11.3 million (Q2 2023), per Business Quant data.